The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model

Cardiovascular Research

Volumn 62, Issue 1, 2004, Pages 105-111

  Kumagai, Koichiro ^a   Nakashima, Hideko ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Arrhythmias; Inflammation; Statins

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIINFLAMMATORY AGENT; ATORVASTATIN; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART ATRIUM CONDUCTION; HEART ATRIUM FIBRILLATION; HEART MUSCLE REFRACTORY PERIOD; MALE; MYOCARDITIS; NONHUMAN; PERICARDITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZATION;

ANIMALS; ARRHYTHMIA; C-REACTIVE PROTEIN; DOGS; FEMALE; HEART ATRIA; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MODELS, ANIMAL; PERICARDITIS; PYRROLES; RANDOM ALLOCATION;

EID: 1542358830     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.01.018     Document Type: Article

References (30)

1. Allessie M.A. Reentrant mechanisms underlying atrial fibrillation. From Cell to Bedside. 2nd ed. Cardiac Electrophysiology. 1995;562-566 Zipes & Jalife, Philadelphia, Saunders.
2. Chung M.K., Martin D.O., Sprecher D.et al. C-reactive protein elevation in patients with atrial arrhythmias. Circulation. 104:2001;2886-2891.
3. Page P.L., Plumb V.J., Okumura K.et al. A new animal model of atrial flutter. J. Am. Coll. Cardiol. 8:1986;872-879.
4. Kumagai K., Khrestian C., Waldo A.L. Simultaneous multisite mapping studies during induced atrial fibrillation in the sterile pericarditis model. Insights into the mechanism of its maintenance. Circulation. 95:1997;511-521.
5. Ridker P.M., Rifai N., Pfeffer M.A.et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 100:1999;230-235.
6. Ridker P.M., Rifai N., Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 103:2001;1191-1193.
7. Strandberg T.E., Vanhanen H., Tikkanen M.J. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet. 353:1999;118-119.
8. Ridker P.M., Rifai N., Clearfield M.et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344:2001;1959-1965.
9. Jialal I., Stein D., Balis D.et al. Effect of hydroxymethyl glutaryl CoA reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 103:2001;1933-1935.
10. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340:1999;448-454.
11. Bruins P., te Velthuis H., Yazdanbakhsh A.P.et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 96:1997;3542-3548.
12. Wijffels M.C., Kirchhof C.J., Dorland R.et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 92:1995;1954-1968.
13. Basso C., Corrado D., Rossi L.et al. Ventricular preexcitation in children and young adults: atrial myocarditis as a possible trigger of sudden death. Circulation. 103:2001;269-275.
14. Rossi L. Histopathological correlates of atrial flutter. Waldo A.L., Touboulm P. Atrial Flutter Advances in Mechanisms and Management. 1996;21-28 Futura Publishing, Armonk, NY.
15. Fromer M., Genton C., Schlapper J.et al. Is there an isolated arrhythmogenic right atrial myocarditis? Eur. Heart J. 11:1990;566-571.
16. Maron D.J., Fazio S., MacRae F.L. Current perspectives on statins. Circulation. 101:2000;207-213.
17. Morrow D.A., Ridker P.M. C-reactive protein, inflammation, and coronary risk. Med. Clin. North Am. 84:2000;149-161.
18. Tracy R.P. Inflammation markers and coronary heart disease. Curr. Opin. Lipidol. 10:1999;435-551.
19. Ridker P.M., Hennekens C.H., Buring J.E.et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342:2000;836-843.
20. Ridker P.M., Rifai N., Pfeffer M.et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98:1998;839-844.
21. Frustaci A., Chimenti C., Bellocci F.et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 96:1997;1180-1184.
22. Lefer A.M., Scalia R., Lefer D.J. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc. Res. 49:2001;281-287.
23. ATP channels in preconditioning. Circ. Res. 87:2000;845-855.
24. Jones S.P., Teshima Y., Akao M.et al. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocites. Circ. Res. 93:2003;697-699.
25. Laufs U., Kilter H., Konkol C.et al. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc. Res. 53:2002;911-920.
26. Ridker P.M., Rifai N., Stampfer M.J.et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 101:2000;1767-1772.
27. Ridker P.M., Buring J.E., Shih J.et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 98:1998;731-733.
28. Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 102:2000;2165-2168.
29. Cermak J., Key N.S., Bach R.R.et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 82:1993;513-520.
30. Siu C.W., Lau C.P., Tse H.F. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am. J. Cardiol. 92:2003;1343-1345.